EHMT2 and breast cancer: Additionally, it downregulates β1- and β3-integrin expression, impairing breast cancer cell migration [28], and decreases histone methyltransferase G9A (EHMT2) expression in alveolar rhabdomyosarcoma cells, underscoring its broad therapeutic potential [49].